Marinomed Biotech AG
ISIN: ATMARINOMED6 | Ticker: MARI | LEI: 529900GN3B1EN80XF405
Country: Austria
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. Marinomed also develops drugs for other serious viral infectious diseases based on iota carrageenan.
Year founded2006
Served areaWorldwide
Headcount37
HeadquartersHovengasse 25, 2100 Korneuburg – Austria
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 23,501,600.00 | 21,337,000.00 | 22,286,600.00 |
| Noncurrent Assets | N/A | 8,105,400.00 | 8,459,600.00 | 8,019,000.00 |
| Property Plant And Equipment | N/A | 6,036,400.00 | 6,431,700.00 | 6,203,300.00 |
| Intangible Assets Other Than Goodwill | N/A | 2,056,800.00 | 2,007,300.00 | 1,804,100.00 |
| Other Noncurrent Nonfinancial Assets | N/A | 12,200.00 | 20,500.00 | 11,600.00 |
| Current Assets | N/A | 15,396,100.00 | 12,877,500.00 | 14,267,500.00 |
| Inventories | N/A | 926,100.00 | 1,027,400.00 | 1,562,100.00 |
| Trade And Other Current Receivables | N/A | 5,263,100.00 | 6,047,900.00 | 4,527,400.00 |
| Current Tax Assets Current | N/A | N/A | 0.00 | 2,800.00 |
| Cash and cash equivalents | 12,019,600.00 | 9,206,900.00 | 5,802,100.00 | 8,175,400.00 |
| Equity And Liabilities | N/A | 23,501,600.00 | 21,337,000.00 | 22,286,600.00 |
| Equity | 10,866,000.00 | 5,357,600.00 | 191,400.00 | -4,157,100.00 |
| Issued Capital | N/A | 1,472,700.00 | 1,480,200.00 | 1,506,200.00 |
| Retained Earnings | N/A | -37,466,300.00 | -43,357,600.00 | -49,755,300.00 |
| Capital Reserve | N/A | 41,351,200.00 | 42,068,800.00 | 44,092,100.00 |
| Noncurrent Liabilities | N/A | 12,535,600.00 | 15,132,000.00 | N/A |
| Other Noncurrent Payables | N/A | 78,500.00 | 87,700.00 | 304,900.00 |
| Longterm Borrowings | N/A | 12,457,100.00 | 15,044,300.00 | 20,182,100.00 |
| Current Liabilities | N/A | 5,608,400.00 | 6,013,700.00 | N/A |
| Other Shortterm Provisions | N/A | 763,000.00 | 0.00 | N/A |
| Trade And Other Current Payables To Trade Suppliers | N/A | 1,975,800.00 | 1,994,900.00 | 1,153,200.00 |
| Other Current Financial Liabilities | N/A | 2,512,700.00 | 3,264,800.00 | 2,357,900.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 8,124,400.00 | 11,627,800.00 | 11,275,900.00 |
| Other Income | 1,161,300.00 | 1,574,600.00 | 837,600.00 |
| Raw Materials And Consumables Used | 5,414,200.00 | 6,428,300.00 | 7,283,000.00 |
| Services Expense | 3,351,900.00 | 3,775,200.00 | 1,852,200.00 |
| Employee Benefits Expense | 4,097,900.00 | 4,461,700.00 | 4,848,700.00 |
| Depreciation And Amortisation Expense | 428,400.00 | 608,900.00 | 669,700.00 |
| Other Expense By Nature | 1,809,200.00 | 2,073,100.00 | 2,373,600.00 |
| Profit Loss From Operating Activities | -5,816,000.00 | -4,144,700.00 | -4,913,600.00 |
| Finance Income | 523,000.00 | 0.00 | 1,194,400.00 |
| Finance Costs | 713,700.00 | 1,549,500.00 | 2,671,700.00 |
| Profit Loss Before Tax | -6,006,700.00 | -5,694,200.00 | -6,390,900.00 |
| Income Tax Expense Continuing Operations | 3,500.00 | 197,100.00 | 6,800.00 |
| Profit (loss) | -6,010,200.00 | -5,891,300.00 | -6,397,700.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -6,010,200.00 | -5,891,300.00 | -6,397,700.00 |
| Adjustments For Finance Costs | N/A | 713,700.00 | 1,549,500.00 | 2,671,700.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 828,600.00 | 101,300.00 | 534,700.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 428,400.00 | 608,900.00 | 669,700.00 |
| Adjustments For Provisions | N/A | 0.00 | 763,000.00 | 0.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 3,500.00 | 197,100.00 | 6,800.00 |
| Cash Flows From Used In Operating Activities | N/A | -6,884,900.00 | -4,866,300.00 | -5,202,900.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | N/A | 0.00 | 20,100.00 |
| Cash Flows From Used In Investing Activities | N/A | -3,963,500.00 | -918,800.00 | -207,500.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 8,000,000.00 | 1,800,000.00 | 6,200,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 78,700.00 | 23,100.00 | 16,400.00 |
| Cash Flows From Used In Financing Activities | N/A | 8,005,600.00 | 2,380,200.00 | 7,783,600.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 2,200.00 | 34,600.00 | 1,400.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -2,812,700.00 | -3,404,800.00 | 2,373,200.00 |
| Cash and cash equivalents | 12,019,600.00 | 9,206,900.00 | 5,802,100.00 | 8,175,400.00 |
Please note that some sums might not add up.
ATMARINOMED6
LEI529900GN3B1EN80XF405
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.